Sigyn Therapeutics, Inc. announced the appointment of Alexander S. Yevzlin, MD, FASN to its Scientific Advisory Board. Dr. Yevzlin's considerable extracorporeal industry experience and insight is expected to contribute to the clinical advancement of Sigyn Therapy. Sigyn Therapy is an extracorporeal blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.25 USD | +5.00% |
|
-.--% | +10.99% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.99% | 6.61M | |
-5.60% | 181B | |
-4.45% | 101B | |
-4.15% | 67.54B | |
-8.63% | 45.09B | |
+9.70% | 44.37B | |
+6.13% | 40.7B | |
+15.22% | 29.85B | |
+14.80% | 24.49B | |
-6.46% | 23.99B |
- Stock Market
- Equities
- SIGY Stock
- News Sigyn Therapeutics, Inc.
- Sigyn Therapeutics, Inc. Appoints Alexander S. Yevzlin to its Scientific Advisory Board